Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

CONTACT-02 : A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

Male<br/>OnlyGender Male
Only

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate
Cancers

Systemic therapy,Treatment | Urinary systemProstate

Trial Overview Read MoreRead more

This phase III trial is comparing a type of targeted therapy with a novel hormonal therapy (NHT) in men who have previously received one NHT for their castration resistant prostate cancer that has spread to other parts of the body.
 

This trial is treating patients with castration resistant prostate cancer .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had a certain type of treatment or surgical procedure.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

Commercial Sponsor

Exelixis

Summary

Eligible patients will be randomised to receive treatment in an Experimental or Control Arm. Patients in the Experimental Arm of the trial will receive 40mg of oral cabozantinib once daily + an 1200mg infusion of atezolizumab every three weeks. Patients in the Control Arm of the trial will receive either 1000mg of oral abiraterone once daily + 5mg of oral prednisone twice daily; OR 160mg of oral enzalutamide once daily, as indicated by the investigator prior to randomisation.

Recruiting Hospitals Read MoreRead more

Grampians Health
Ballarat
Ms Carmel Goss
CarmelG@bhs.org.au
03 5320 4735

Peninsula Health
Frankston
Ms Linda Raineri
lraineri@phcn.vic.gov.au
03 9784 7175

Barwon Health, University Hospital Geelong
Geelong
Oncology Team
OncologyTrials@barwonhealth.org.au

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Richelle Linklater
PCCTU.MoncA@petermac.org

Western Health - Sunshine Hospital
St Albans
Ms Heike Raunow
CancerClinicalTrials@wh.org.au
0434 915 739

Not Recruiting Hospitals Read MoreRead more

Closed

Box Hill Hospital Medical Oncology
Box Hill
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next